1. Association between change in body mass index and risk of hypertension and dyslipidemia in people receiving integrase inhibitors and/or tenofovir alafenamide compared to other contemporary antiretroviral regimens: the RESPOND consortium of prospective cohorts  Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, D’Arminio Monforte A, Mussini C, Wasmuth J-C, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K, on behalf of the RESPOND study group
    Lancet HIV, 2023.